OSE Immunotherapeutics SA (FR:OSE)
:OSE
Want to see FR:OSE full AI Analyst Report?
Top Page
OSE Immunotherapeutics SA
(OSE)
Select Model
Select Model
Rating:42Neutral
Price Target:
€4.00
▲(20.12% Upside)
Action:Reiterated
Date:06/08/26
The score is held down primarily by weak and volatile financial performance, including a sharp 2025 reversal into heavy losses and cash burn alongside meaningful leverage. Technical indicators also point to a bearish trend (below key moving averages with negative MACD), while valuation offers limited support due to the negative P/E and no provided dividend yield.
Positive Factors
Targeted Biotech Focus
OSE’s clear, durable focus on immuno-oncology and immuno-inflammation positions it in large, structural markets for immune-modulating therapies. A focused R&D strategy supports sustained scientific differentiation and repeatable program-level value creation attractive to partners over the medium term.
Negative Factors
Revenue Volatility
A dramatic revenue collapse indicates heavy reliance on episodic partnership or milestone receipts, undermining predictable funding and operational planning. Over the next several months this volatility increases execution and financing risk, complicating sustained R&D progress without new deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted Biotech Focus
OSE’s clear, durable focus on immuno-oncology and immuno-inflammation positions it in large, structural markets for immune-modulating therapies. A focused R&D strategy supports sustained scientific differentiation and repeatable program-level value creation attractive to partners over the medium term.
Read all positive factors
OSE Immunotherapeutics SA (OSE) vs. iShares MSCI France ETF (EWQ)
Market Cap
€81.17M
Dividend YieldN/A
Average Volume (3M)154.47K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth-96.25%
EPS Growth-197.89%
CountryFR
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.69
Shares Outstanding22,680,110
10 Day Avg. Volume172,695
30 Day Avg. Volume154,469
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.20
Price to Sales (P/S)43.87
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.20Price Target Upside146.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.22
Revenue Forecast (FY)€6.17M
OSE Immunotherapeutics SA Business Overview & Revenue Model
Company Description
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline fea...
How the Company Makes Money
OSE Immunotherapeutics primarily generates (or seeks to generate) revenue through (1) partnering and licensing its drug candidates and technology platforms to larger biopharma companies and (2) equity financing typical of clinical-stage biotech co...
OSE Immunotherapeutics SA Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
46
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.62M | 69.88M | 2.23M | 18.30M | 26.31M |
| Gross Profit | 2.62M | 69.88M | 2.23M | 18.30M | 26.31M |
| EBITDA | -44.81M | 41.20M | -17.50M | -13.11M | -13.72M |
| Net Income | -37.70M | 37.45M | -23.00M | -17.76M | -16.85M |
Balance Sheet | |||||
| Total Assets | 78.44M | 123.96M | 82.05M | 91.67M | 101.52M |
| Cash, Cash Equivalents and Short-Term Investments | 22.65M | 16.75M | 18.67M | 25.62M | 33.58M |
| Total Debt | 35.38M | 46.13M | 45.80M | 44.79M | 37.13M |
| Total Liabilities | 51.10M | 60.15M | 59.08M | 59.12M | 53.99M |
| Stockholders Equity | 27.34M | 63.81M | 22.82M | 32.55M | 47.89M |
Cash Flow | |||||
| Free Cash Flow | -34.13M | 48.36M | -20.00M | -18.53M | -10.39M |
| Operating Cash Flow | -34.03M | 48.44M | -19.76M | -18.25M | -9.92M |
| Investing Cash Flow | 41.35M | -46.91M | -507.00K | 26.00K | -827.00K |
| Financing Cash Flow | -6.51M | -3.46M | 13.32M | 10.27M | 14.96M |
OSE Immunotherapeutics SA Technical Analysis
Negative
3.33
Price Trends
3.98
Negative
4.00
Negative
4.79
Negative
Market Momentum
-0.14
Positive
41.95
Neutral
30.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:OSE, the sentiment is Negative. The current price of 3.33 is below the 20-day moving average (MA) of 4.11, below the 50-day MA of 3.98, and below the 200-day MA of 4.79, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 41.95 is Neutral, neither overbought nor oversold. The STOCH value of 30.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:OSE.
OSE Immunotherapeutics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €150.06M | -2.97 | -658.91% | ― | -77.92% | 11.11% | |
48 Neutral | €208.49M | -3.19 | -634.16% | ― | 291.43% | 12.24% | |
44 Neutral | €6.88B | -17.83 | ― | ― | ― | ― | |
43 Neutral | €194.99M | -4.62 | -30.75% | ― | 32.62% | -7.59% | |
42 Neutral | €81.17M | -2.13 | -52.76% | ― | -96.25% | -197.89% | |
42 Neutral | €53.93M | -1.55 | ― | ― | 40.67% | 11.49% |
* Healthcare Sector Average
FR:OSE
OSE Immunotherapeutics SA
3.49
-1.45
-29.40%
FR:IPH
Innate Pharma SA
1.61
0.02
1.20%
FR:ABVX
Abivax SA
85.05
79.80
1520.00%
FR:TNG
Transgene
0.75
-0.14
-16.07%
FR:ALCLS
Cellectis SA
2.67
1.39
109.25%
FR:MAAT
MaaT Pharma
2.86
-2.35
-45.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.